. 2023 May 22;8(8):1506–1513. doi: 10.1016/j.ekir.2023.05.010

Table 2.

Characteristics of patients with COVID-19 or SARS-CoV-2 vaccination associated TMA

						TMA diagnosis
Patien number	Sex	Age	Event	Time to TMA from event^b	Native kidney; kindey graft	SCr	PLT	LDH	UPCR	Kidneybiopsy	TMA treatment	Outcome3 mo
7^a	M	34	COV	44	G	6.28	207	252	4746	active TMA	5× PLEX	SCr 6.78
9^a	F	32	COV	28	G	1.54	355	203	3425	TMA vs. ABMR	on antiC5	SCr 1.66
24^a	F	21	COV	16	N	18.96	124	422	n.a.	n.a.	anti C5	chronic HD
27^a	M	67	VAC	10	G	2.54	132	277	3246	relapsing TMA	antiC5	SCr 2.63

ABMR, antibody mediated rejection; anti C5, eculizumab or ravulizumab therapy; CFH, complement factor H; COV, coronavirus disease 19; F, female; G, kidney graft; HD, hemodialysis; LDH, lactate dehydrogenase (reference range: <250 U/l); M, male; N, native kidney; n.a., not available; PLEX, plasma exchange; PLT, platelet count (reference range: 150-350 G/L); SCr, serum creatinine in mg/dl; TMA, thrombotic microangiopathy; UPCR, urinary protein to creatinine ratio (reference range: <200 mg/g); VAC, SARS-CoV-2 vaccination.

TMA relapse.

In days.